Alcon reports Q3 2026 sales growth, narrows full‑year outlook and guidance
Alcon posted third‑quarter 2026 net sales of $2.7 billion, up 5% year‑over‑year on both a reported and constant‑currency basis. Core diluted earnings per share rose 15% to $0.91, while implantable lens sales fell 2% to $422 million. The company trimmed its fiscal‑2026 guidance, now targeting about 6% constant‑currency sales growth and core EPS growth of 12%–14%, and lowered its market‑growth outlook to roughly 3%. The guidance revision prompted a sell‑off, with the stock dropping 5%–6% on the day.
Why it matters
The tighter sales and EPS guidance reduces investors’ expectations for Alcon’s 2026 earnings trajectory, which contributed to a 5%‑6% share‑price decline. The lower market‑growth outlook also signals heightened competitive pressure in the eye‑care sector.
Key facts
- 1Q3 2026 net sales were $2.7 billion, up 5% on a reported and constant‑currency basis versus Q3 2025. finanznachrichten.de
- 2Core diluted EPS for Q3 2026 was $0.91, up 15% on a reported and constant‑currency basis versus Q3 2025. finanznachrichten.de
- 3Implantable lens sales declined 2% in Q3 2026 to $422 million. wfmz.com
- 4Alcon now expects full‑year 2026 sales growth of about 6% constant currency. tradingview.com
- 5Core EPS growth guidance for 2026 was narrowed to 12%–14%. tradingview.com
- 6The company lowered its 2026 market‑growth outlook to roughly 3%. kelo.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.